Spruce Biosciences, Inc.: Form 10-Q for the period ended Jun 30, 2024
Filed with the SEC on Aug 12, 2024 and accepted by EDGAR at Aug 12, 2024, 16:18 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-04-01 to 2024-06-30 | $1.6m | us-gaap:Revenues |
| Revenue | 6 months2024-01-01 to 2024-06-30 | $3.6m | us-gaap:Revenues |
| Research and development | 3 months2024-04-01 to 2024-06-30 | $8.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2024-01-01 to 2024-06-30 | $18.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-04-01 to 2024-06-30 | −$10.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2024-01-01 to 2024-06-30 | −$22.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2024-04-01 to 2024-06-30 | $83.0k | us-gaap:InterestExpense |
| Interest expense | 6 months2024-01-01 to 2024-06-30 | $180.0k | us-gaap:InterestExpense |
| Net income | 3 months2024-04-01 to 2024-06-30 | −$9.2m | us-gaap:NetIncomeLoss |
| Net income | 6 months2024-01-01 to 2024-06-30 | −$20.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-04-01 to 2024-06-30 | −$0.22 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2024-01-01 to 2024-06-30 | −$0.51 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-04-01 to 2024-06-30 | −$0.22 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2024-01-01 to 2024-06-30 | −$0.51 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-04-01 to 2024-06-30 | 41,163,209 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2024-01-01 to 2024-06-30 | 41,129,719 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2024-01-01 to 2024-06-30 | −$26.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2024-06-30 | $69.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-06-30 | $73.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-06-30 | $75.5m | us-gaap:Assets |
| Current liabilities | At period end2024-06-30 | $14.3m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-06-30 | $16.4m | us-gaap:Liabilities |
| Long-term debt | At period end2024-06-30 | $923.0k | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2024-06-30 | $1.6m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2024-06-30 | $59.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-24-095461. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.